Observational program, double-blind, placebo-controlled to study the preventive efficacy of the BiVac polio (Oral polio vaccine, divalent, live attenuated of types 1 and 3 vaccine against the incidence of acute respiratory infections, including COVID-19
To carry out a comparative assessment of the indices of humoral, cellular immunity and cytokine profile in patients with acute respiratory infections. Current Program Population: 1500 healthy male and female volunteers, aged of between 18 and 65 will be included in the program. All included volunteers will be divided into groups: Group 1 - 750 volunteers who will be vaccinated with BiVac polio vaccine; post-vaccination observation period of 12 months. Group 2 - 750 volunteers, placebo will be administered, post-vaccination observation period of 12 months. The probability of getting into one of the two groups for each volunteer will be 50%.
Study Type
OBSERVATIONAL
Enrollment
1,500
Federal State Budgetary Educational Institution of Higher Education Kirov State Medical University of the Ministry of Health of Russia
Kirov, Russia
The number of detected cases
The number of detected cases confirmed by laboratory (PCR and / or serological tests).
Time frame: within 12 months by groups
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.